Skip to content
Screener

Madrigal Pharmaceuticals, Inc. MDGL Q4 2025 Annual earnings

Reported February 19, 2026 · Before market open

Revenue$321.1MBeat by $8.6M
EPS-$2.57Miss by $2.61
Revenue estimate$312.5M
EPS estimate$0.04

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$404.2M
EPS estimate-$0.86

Financials

Q4 2025

Income statement

See full
Revenue$321.1M+211%
Operating income-$59.6M+11.0%
Net income-$58.6M+1.4%
EPS (diluted)-$2.53+2.3%

Balance sheet

See full
Cash & equivalents$203.8M+94.0%
Total debt$347.6M+191%
Total equity$602.7M-20.1%
Total assets$1.3B+20.9%

Cash flow

See full
Operating cash flow-$133.5M-27.7%
Free cash flow-$133.1M-27.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$13.23B+96.5%
Enterprise value$13.37B+98.2%
P/S13.8×-23.6×

Profitability

See full
Operating margin-31.3%-14.7pp
Net margin-30.1%-14.1pp

Returns & leverage

See full
Return on equity-42.5%-13.6pp
Debt / equity0.6×+0.4×
Current ratio4×-2.1×

Segments

By segment

See full
Reportable Segment$321.1M+211%

FAQ

When did Madrigal Pharmaceuticals, Inc. report Q4 2025 earnings?
Madrigal Pharmaceuticals, Inc. (MDGL) reported Q4 2025 earnings on February 19, 2026 before market open.
What were Madrigal Pharmaceuticals, Inc.'s Q4 2025 revenue and EPS?
Madrigal Pharmaceuticals, Inc. reported revenue of $321.1M and eps of $-2.57 for Q4 2025.
Did Madrigal Pharmaceuticals, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $312.5M by $8.6M. EPS missed the consensus estimate of $0.04 by $2.61.
How did Madrigal Pharmaceuticals, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 210.8% from $103.3M a year earlier and eps grew 5.2% from $-2.71.
Where can I find Madrigal Pharmaceuticals, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-009476) and the 10-K periodic report (0001628280-26-009514) directly on SEC EDGAR. The filing index links above go to sec.gov.